{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,1]],"date-time":"2026-07-01T22:55:15Z","timestamp":1782946515191,"version":"3.54.5"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100007959","name":"Chulabhorn Research Institute, Thailand","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007959","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>To investigate whether the inhibitions of ataxia-telangiectasia mutated (ATM) and ATM- and Rad3-related (ATR) kinases by their specific inhibitors, KU-55933 and VE-821, respectively, are able to promote the cytotoxic activity of genotoxic agents including gemcitabine, 5-Fluorouracil, cisplatin and doxorubicin, in cholangiocarcinoma (CCA) and immortalized cholangiocyte cell lines.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Cell viability of cells treated with DNA damaging agents, alone and in combination with KU-55933 and VE-821, was determined by MTT assay. The changes of cell cycle distribution were evaluated by flow cytometry analysis. Colony formation was conducted to assess the effects of KU-55933 and VE-821 on cell proliferation. The levels of protein expression and phosphorylation were examined by western blot analysis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Key findings<\/jats:title>\n                  <jats:p>The cytotoxic effects of DNA damaging agents varied among CCA cell lines. Each DNA damaging drug induced different phases of the cell cycle in CCA cells. The combinations of both KU-55933 and VE-821 with DNA damaging agents promoted more cytotoxic activity than single inhibition in some CCA cell lines. ATM and ATR inhibitors decreased the effects of DNA damaging agent-induced ATM-Chk2 and ATR-Chk1 activations in CCA cells.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Inhibitions of ATM and ATR potentiated the cytotoxic effects of DNA damaging agents in CCA cells, especially p53 defective HuCCA1 and RMCC1 cell lines.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jpp\/rgaa050","type":"journal-article","created":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T04:13:53Z","timestamp":1609474433000},"page":"40-51","source":"Crossref","is-referenced-by-count":6,"title":["The antiproliferative effects of ataxia-telangiectasia mutated and ATM- and Rad3-related inhibitions and their enhancements with the cytotoxicity of DNA damaging agents in cholangiocarcinoma cells"],"prefix":"10.1093","volume":"73","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2008-4021","authenticated-orcid":false,"given":"Benchamart","family":"Moolmuang","sequence":"first","affiliation":[{"name":"Laboratory of Chemical Carcinogenesis, Chulabhorn Research Institute , Bangkok,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mathuros","family":"Ruchirawat","sequence":"additional","affiliation":[{"name":"Laboratory of Environmental Toxicology, Chulabhorn Research Institute , Bangkok,","place":["Thailand"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,1,1]]},"reference":[{"key":"2024103012051740800_CIT0001","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/0140-6736(90)90591-R","article-title":"Cholangiocarcinoma in north-east Thailand","volume":"335","author":"Vatanasapt","year":"1990","journal-title":"Lancet"},{"key":"2024103012051740800_CIT0002","first-page":"537","article-title":"Cholangiocarcinoma: epidemiology, mechanisms of carcinogenesis and prevention","volume":"2","author":"Parkin","year":"1993","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"key":"2024103012051740800_CIT0003","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1136\/gutjnl-2011-301748","article-title":"Guidelines for the diagnosis and treatment of cholangiocarcinoma: an update","volume":"61","author":"Khan","year":"2012","journal-title":"Gut"},{"key":"2024103012051740800_CIT0004","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1634\/theoncologist.2007-0252","article-title":"Systemic therapy for biliary tract cancers","volume":"13","author":"Hezel","year":"2008","journal-title":"Oncologist"},{"key":"2024103012051740800_CIT0005","doi-asserted-by":"crossref","first-page":"vii73","DOI":"10.1093\/annonc\/mdl956","article-title":"Gemcitabine and cisplatin for inoperable and\/or metastatic biliary tree carcinomas: a multicenter phase II study of the Gruppo Oncologico dell\u2019Italia Meridionale (GOIM)","volume":"17","author":"Giuliani","year":"2006","journal-title":"Ann Oncol"},{"key":"2024103012051740800_CIT0006","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1038\/sj.bjc.6603648","article-title":"Chemotherapy in advanced biliary tract carcinoma: a pooled analysis of clinical trials","volume":"96","author":"Eckel","year":"2007","journal-title":"Br J Cancer"},{"key":"2024103012051740800_CIT0007","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/cncr.20753","article-title":"Gemcitabine, 5-fluorouracil, and leucovorin in advanced biliary tract and gallbladder carcinoma: a North Central Cancer Treatment Group phase II trial","volume":"103","author":"Alberts","year":"2005","journal-title":"Cancer"},{"key":"2024103012051740800_CIT0008","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/nrc2342","article-title":"DNA repair pathways as targets for cancer therapy","volume":"8","author":"Helleday","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"2024103012051740800_CIT0009","doi-asserted-by":"crossref","first-page":"1448","DOI":"10.1101\/gad.14.12.1448","article-title":"Chk1 is an essential kinase that is regulated by Atr and required for the G(2)\/M DNA damage checkpoint","volume":"14","author":"Liu","year":"2000","journal-title":"Genes Dev"},{"key":"2024103012051740800_CIT0010","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.ctrv.2013.03.002","article-title":"Targeting ATR in DNA damage response and cancer therapeutics","volume":"40","author":"Fokas","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"2024103012051740800_CIT0011","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/B978-0-12-380888-2.00003-0","article-title":"The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer","volume":"108","author":"Smith","year":"2010","journal-title":"Adv Cancer Res"},{"key":"2024103012051740800_CIT0012","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/ncb2897","article-title":"Causes and consequences of replication stress","volume":"16","author":"Zeman","year":"2014","journal-title":"Nat Cell Biol"},{"key":"2024103012051740800_CIT0013","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.pharmthera.2014.12.001","article-title":"ATM and ATR as therapeutic targets in cancer","volume":"149","author":"Weber","year":"2015","journal-title":"Pharmacol Ther"},{"key":"2024103012051740800_CIT0014","article-title":"Targeting the ATR-CHK1 axis in cancer therapy","volume":"9,41","author":"Rundle","year":"2017","journal-title":"Cancers (Basel)"},{"key":"2024103012051740800_CIT0015","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3389\/fonc.2017.00098","article-title":"Targeting ongoing DNA damage in multiple myeloma: effects of DNA damage response inhibitors on plasma cell survival","volume":"7","author":"Herrero","year":"2017","journal-title":"Front Oncol"},{"key":"2024103012051740800_CIT0016","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1126\/science.281.5383.1674","article-title":"Enhanced phosphorylation of p53 by ATM in response to DNA damage","volume":"281","author":"Banin","year":"1998","journal-title":"Science"},{"key":"2024103012051740800_CIT0017","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1101\/gad.14.3.278","article-title":"Chk2\/hCds1 functions as a DNA damage checkpoint in G(1) by stabilizing p53","volume":"14","author":"Chehab","year":"2000","journal-title":"Genes Dev"},{"key":"2024103012051740800_CIT0018","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1038\/nrm2450","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","journal-title":"Nat Rev Mol Cell Biol"},{"key":"2024103012051740800_CIT0019","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1158\/1078-0432.CCR-09-1029","article-title":"New insights into checkpoint kinase 1 in the DNA damage response signaling network","volume":"16","author":"Dai","year":"2010","journal-title":"Clin Cancer Res"},{"key":"2024103012051740800_CIT0020","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.dnarep.2018.04.004","article-title":"Advances in therapeutic targeting of the DNA damage response in cancer","volume":"66\u201367","author":"Desai","year":"2018","journal-title":"DNA Repair (Amst)"},{"key":"2024103012051740800_CIT0021","doi-asserted-by":"crossref","first-page":"e441","DOI":"10.1038\/cddis.2012.181","article-title":"Targeting ATR in vivo using the novel inhibitor VE-822 results in selective sensitization of pancreatic tumors to radiation","volume":"3","author":"Fokas","year":"2012","journal-title":"Cell Death Dis"},{"key":"2024103012051740800_CIT0022","doi-asserted-by":"crossref","first-page":"3683","DOI":"10.1158\/0008-5472.CAN-13-0110","article-title":"ATR inhibition broadly sensitizes ovarian cancer cells to chemotherapy independent of BRCA status","volume":"73","author":"Huntoon","year":"2013","journal-title":"Cancer Res"},{"key":"2024103012051740800_CIT0023","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/bjc.2012.265","article-title":"Targeting radiation-resistant hypoxic tumour cells through ATR inhibition","volume":"107","author":"Pires","year":"2012","journal-title":"Br J Cancer"},{"key":"2024103012051740800_CIT0024","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4161\/cbt.21093","article-title":"The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy","volume":"13","author":"Prevo","year":"2012","journal-title":"Cancer Biol Ther"},{"key":"2024103012051740800_CIT0025","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00411-013-0486-5","article-title":"Inhibition of ATR kinase with the selective inhibitor VE-821 results in radiosensitization of cells of promyelocytic leukaemia (HL-60)","volume":"52","author":"V\u00e1vrov\u00e1","year":"2013","journal-title":"Radiat Environ Biophys"},{"key":"2024103012051740800_CIT0026","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.4161\/cc.11.6.19576","article-title":"Dynamic inhibition of ATM kinase provides a strategy for glioblastoma multiforme radiosensitization and growth control","volume":"11","author":"Golding","year":"2012","journal-title":"Cell Cycle"},{"key":"2024103012051740800_CIT0027","doi-asserted-by":"crossref","first-page":"7466","DOI":"10.1158\/0008-5472.CAN-08-0763","article-title":"Transient inhibition of ATM kinase is sufficient to enhance cellular sensitivity to ionizing radiation","volume":"68","author":"Rainey","year":"2008","journal-title":"Cancer Res"},{"key":"2024103012051740800_CIT0028","doi-asserted-by":"crossref","first-page":"9152","DOI":"10.1158\/0008-5472.CAN-04-2727","article-title":"Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM","volume":"64","author":"Hickson","year":"2004","journal-title":"Cancer Res"},{"key":"2024103012051740800_CIT0029","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/nchembio.573","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","journal-title":"Nat Chem Biol"},{"key":"2024103012051740800_CIT0030","doi-asserted-by":"crossref","first-page":"3392","DOI":"10.3748\/wjg.v11.i22.3392","article-title":"Establishment and characterization of an opisthorchiasis-associated cholangiocarcinoma cell line (KKU-100)","volume":"11","author":"Sripa","year":"2005","journal-title":"World J Gastroenterol"},{"key":"2024103012051740800_CIT0031","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/01.TP.0000110292.73873.25","article-title":"Establishment of a highly differentiated immortalized human cholangiocyte cell line with SV40T and hTERT","volume":"77","author":"Maruyama","year":"2004","journal-title":"Transplantation"},{"key":"2024103012051740800_CIT0032","first-page":"153","article-title":"Establishment and characterization of a cholangiocarcinoma cell line from a Thai patient with intrahepatic bile duct cancer","volume":"9","author":"Sirisinha","year":"1991","journal-title":"Asian Pac J Allergy Immunol"},{"key":"2024103012051740800_CIT0033","doi-asserted-by":"crossref","first-page":"6500","DOI":"10.3748\/wjg.v12.i40.6500","article-title":"Establishment and characterization of a cholangiocarcinoma cell line (RMCCA-1) from a Thai patient","volume":"12","author":"Rattanasinganchan","year":"2006","journal-title":"World J Gastroenterol"},{"key":"2024103012051740800_CIT0034","first-page":"3976","article-title":"Specific proteolytic cleavage of poly(ADP-ribose) polymerase: an early marker of chemotherapy-induced apoptosis","volume":"53","author":"Kaufmann","year":"1993","journal-title":"Cancer Res"},{"key":"2024103012051740800_CIT0035","doi-asserted-by":"crossref","first-page":"2748","DOI":"10.3748\/wjg.v11.i18.2748","article-title":"Drug sensitivity and drug resistance profiles of human intrahepatic cholangiocarcinoma cell lines","volume":"11","author":"Tepsiri","year":"2005","journal-title":"World J Gastroenterol"},{"key":"2024103012051740800_CIT0036","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3892\/ol.2015.3458","article-title":"Combined paclitaxel, cisplatin and fluorouracil therapy enhances ionizing radiation effects, inhibits migration and induces G0\/G1 cell cycle arrest and apoptosis in oral carcinoma cell lines","volume":"10","author":"Elias","year":"2015","journal-title":"Oncol Lett"},{"key":"2024103012051740800_CIT0037","doi-asserted-by":"crossref","first-page":"3768","DOI":"10.4161\/cc.10.21.17972","article-title":"Activation of DNA damage response pathways in human mesenchymal stem cells exposed to cisplatin or \u03b3-irradiation","volume":"10","author":"Prendergast","year":"2011","journal-title":"Cell Cycle"},{"key":"2024103012051740800_CIT0038","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1124\/mol.109.055178","article-title":"Cisplatin-induced DNA damage activates replication checkpoint signaling components that differentially affect tumor cell survival","volume":"76","author":"Wagner","year":"2009","journal-title":"Mol Pharmacol"},{"key":"2024103012051740800_CIT0039","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1016\/j.dnarep.2013.10.004","article-title":"Investigation of switch from ATM to ATR signaling at the sites of DNA damage induced by low and high LET radiation","volume":"12","author":"Saha","year":"2013","journal-title":"DNA Repair (Amst)"},{"key":"2024103012051740800_CIT0040","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1002\/jcp.20700","article-title":"ATR dependent activation of Chk2","volume":"208","author":"Wang","year":"2006","journal-title":"J Cell Physiol"},{"key":"2024103012051740800_CIT0041","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1158\/1535-7163.MCT-16-0378","article-title":"AZD6738, a novel oral inhibitor of ATR, induces synthetic lethality with ATM deficiency in gastric cancer cells","volume":"16","author":"Min","year":"2017","journal-title":"Mol Cancer Ther"},{"key":"2024103012051740800_CIT0042","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/nrc1011","article-title":"ATM and related protein kinases: safeguarding genome integrity","volume":"3","author":"Shiloh","year":"2003","journal-title":"Nat Rev Cancer"},{"key":"2024103012051740800_CIT0043","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1101\/gad.13.2.152","article-title":"A role for ATR in the DNA damage-induced phosphorylation of p53","volume":"13","author":"Tibbetts","year":"1999","journal-title":"Genes Dev"}],"container-title":["Journal of Pharmacy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/73\/1\/40\/60216695\/rgaa050.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpp\/article-pdf\/73\/1\/40\/60216695\/rgaa050.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T16:42:47Z","timestamp":1730306567000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpp\/article\/73\/1\/40\/6118662"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,1]]},"references-count":43,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,1,1]]},"published-print":{"date-parts":[[2021,1,1]]}},"URL":"https:\/\/doi.org\/10.1093\/jpp\/rgaa050","relation":{},"ISSN":["0022-3573","2042-7158"],"issn-type":[{"value":"0022-3573","type":"print"},{"value":"2042-7158","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2021,1,1]]},"published":{"date-parts":[[2021,1,1]]}}}